Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decitabine dosing schedules.

Hagop M Kantarjian1, Jean-Pierre J Issa

  • 1Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. hkantarj@mdanderson.org

Seminars in Hematology
|July 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.

Cancer·2017
Same author

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

Experimental hematology & oncology·2017
Same author

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

American journal of hematology·2017
Same author

Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia.

Clinical lymphoma, myeloma & leukemia·2017
Same author

Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.

Cancer·2017
Same author

US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.

Blood advances·2017
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

5-Aza-2'-deoxycytidine (decitabine) inhibits DNA methyltransferases, leading to gene re-expression. Lower doses show promise for treating hematologic malignancies, with optimal dosing and delivery methods still under investigation.

Area of Science:

  • Epigenetics
  • Pharmacology
  • Oncology

Background:

  • 5-Aza-2 -deoxycytidine (decitabine) is a cytidine analog that inhibits DNA methyltransferases.
  • Decitabine's mechanism involves DNA hypomethylation and subsequent gene re-expression.
  • The compound exhibits dual activity: cytotoxic at high doses and demethylating at lower doses.

Purpose of the Study:

  • To review the mechanism of action and clinical applications of decitabine.
  • To evaluate the efficacy of decitabine in hematologic malignancies.
  • To identify optimal dosing schedules and delivery methods for decitabine.

Main Methods:

  • Review of existing literature on decitabine's synthesis, mechanism, and clinical trials.
  • Analysis of data from sequential and randomized phase I/II studies.

Related Experiment Videos

  • Comparison of different dosing schedules and administration routes (short infusion vs. continuous infusion).

    • Main Results:

    • Lower doses of decitabine are associated with demethylating activity and are less toxic than high doses.
    • Decitabine shows promise in treating hematologic malignancies when administered at lower doses.
    • Short infusions of decitabine appear more active and less toxic than continuous infusions.
    • Higher dose-intensity correlates with increased response rates, suggesting a link between peak drug levels and efficacy.

    Conclusions:

    • Decitabine is a promising demethylating agent for hematologic malignancies.
    • Optimal dosing and administration schedules, possibly via short infusions, require further investigation.
    • Development of alternative formulations for decitabine may improve therapeutic outcomes.